Compare SSYS & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSYS | VALN |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.7M | 653.3M |
| IPO Year | 2012 | 2021 |
| Metric | SSYS | VALN |
|---|---|---|
| Price | $8.14 | $6.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $12.33 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 664.9K | 27.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $3.23 | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $4.75 |
| 52 Week High | $12.78 | $12.23 |
| Indicator | SSYS | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 54.11 |
| Support Level | $7.47 | $6.29 |
| Resistance Level | $8.20 | $6.60 |
| Average True Range (ATR) | 0.26 | 0.21 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 72.16 | 23.72 |
Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.